Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.86 HKD | -2.82% | -4.25% | -12.28% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.28% | 534M | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics : Luye Pharma Dose First Patient in Phase III Trial of Eye Drug in China